Chemed (CHE) CEO granted 58,672 options at $443.79
Chemed Corp (CHE) reported an insider equity award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Chemed Corp (CHE) reported an insider equity award. CEO and Director Kevin J. McNamara received a grant of stock options covering 58,672 shares on 10/21/2025, with an exercise price of $443.79 per share. The options expire on 10/21/2030 and vest in three equal annual installments starting 10/21/2026. Following this award, he directly holds 266,159 derivative securities. No non-derivative transactions were listed in the excerpt.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy with tandem tax withholding) | 58,672 | $443.79 | $26.04M |
Footnotes (1)
- F1. Vesting in three equal annual installments commencing 10/21/2026
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CHE’s CEO report on Form 4?
What is the exercise price of the CHE stock options?
When do the CHE options vest for the CEO?
What is the expiration date of the options?
How many derivative securities does the CEO hold after the grant?
What is CHE’s ticker symbol?
AI-generated analysis. How Rhea-AI works. Not financial advice.